Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2Terminated 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 217Neoplasms 178Lung Neoplasms 94Prostatic Neoplasms 90Colorectal Neoplasms 89Carcinoma, Non-Small-Cell Lung 49Motor Activity 47Stomach Neoplasms 45Carcinoma, Hepatocellular 45Pancreatic Neoplasms 40Uterine Cervical Neoplasms 39Anxiety Disorders 39Rectal Neoplasms 34Colonic Neoplasms 31Head and Neck Neoplasms 30Pain 26Depression 26Esophageal Neoplasms 24Brain Neoplasms 24Disease 23Polycystic Ovary Syndrome 22Hematologic Neoplasms 22Endometrial Neoplasms 22Multiple Myeloma 21Ovarian Neoplasms 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Urinary Bladder Neoplasms 18Pain, Postoperative 18Leukemia, Myeloid, Acute 17Liver Neoplasms 16

Interventions

telitacicept 1Population Groups 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Not yet recruiting × Neuromuscular Diseases × Clear all
NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase NA Not yet recruiting
60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡